Welcome to Cabometyx.no website. This website is intended for Norway Healthcare professionals only.
Please confirm below that you are a registered healthcare professional.
I AM A NORWEGIAN HEALTHCARE PROFESSIONAL
CABOMETYX® (cabozantinib) Abbreviations
| (a)HCC | (advanced) Hepatocellular Carcinoma |
| (a)RCC | (advanced) Renal Cell Carcinoma |
| (HR)QoL | (Health Related) Quality of Life |
| (m)RECIST | (modified) Response Evaluation Criteria In Solid Tumors |
| AE | Adverse Event |
| AFP | Alpha FetoProtein |
| AASLD | American Association for the Study of Liver Disease |
| ASCO | American Society of Clinical Oncology |
| A-Pac | Asia Pacific |
| A&U | Awareness and Usage |
| BCLC | Barcelona Clinic Liver Cancer |
| BSC | Best Supportive Care |
| BMS | Bristol Myers Squibb |
| BU | Business Unit |
| CRPC | Castration Resistant Prostate Cancer |
| CPI | Check Point Inhibitor |
| CM | CheckMate |
| CP-A | Child Pugh-A |
| CSR | Clinical Study Report |
| CHMP | Committee for Medicinal Products for Human Use |
| CT-Scan | Computed Tomography Scan |
| CME | Continuing Medical Education |
| CSF | Critical Success Factor |
| DCR | Disease Control Rate |
| DoT | Duration of Treatment |
| ECOG | Eastern Cooperative Oncology Group |
| ER | Emergency |
| EASL | European Association for the Study of the Liver |
| EAU | European Association of Urology |
| EC | European Commission |
| EFPIA | European Federation of Pharmaceutical Industries and Associations |
| EIKCS | European International Kidney Cancer Symposium |
| ELPA | European Liver Patient Association |
| EMA | European Medicine Agency |
| ESMO | European Society of Molecular Oncology |
| EU | European Union |
| G-BA | German Federal Joint Committee |
| 1L / 2L | First line / Second Line |
| FPI | First Patient In |
| FDA | Food and Drug Administration |
| FYROM | Former Yugoslavian Republic of Macedonia |
| EU5 | France, Germany, Italy, Spain, UK |
| EU3 | France, Germany, UK |
| GI | Gastro Intestinal |
| GE | GastroEnteric |
| GU | GenitoUrinary |
| DACH | Germany, Austria, Switzerland |
| GCSP | Globcal Cabometyx Strategic Plan |
| GAS-6 | Growth arrest-specific 6 (AXL ligand) |
| HAS | Haute Autorité de Santé (French National Authority for Health) |
| HR | Hazard Ratio |
| HCP | Health Care Provider |
| HEOR | Health Economics Outcome Research |
| HTA | Health Technology Assessment |
| HBV | Hepatitis B Virus |
| HCV | Hepatitis C Virus |
| HGF | Hepatocyte Growth Factor (MET ligand) |
| MET | Hepatocyte growth factor receptor |
| HEP | Hepatologists |
| IME | Independent Medical Education |
| IRC | Independent Review Committee |
| IDO-1 | Indoleamine-pyrrole 2,3-dioxygenase |
| IKCC | International Kidney Cancer Coalition |
| ILCA | International Liver Cancer Association |
| IIME | Ipsen Initiated Medical Education |
| ISS | Ipsen Sponsored Study |
| KAM | Key Account Manager |
| KPI | Key Performance Indicator |
| LPI | Last Patient In |
| LPLV | Last Patient Last Visit |
| LCM | Life Cycle Management |
| LDT | Liver Directed Therapies |
| mToR | mammalian Target of Rapamycin |
| MEA | Managed Entry Agreement |
| MoA | Mechanism of Action |
| MTC | Medullary Thyroid Cancer |
| MSD | Merck Sharp and Dohme |
| MC(M) | MultiChannel (Marketing) |
| NICE | National Institute for Health and Care Excellence |
| NMA | Network Meta Analysis |
| NIS | Non Interventional Study |
| NSCLC | Non Small Cell Lung Cancer |
| Nordics | Norway, Sweden, Finland, Denmark |
| NA | Not Available |
| NR | Not Reached |
| ISPOR | International Society for Pharmacoeconomics and Outcomes Research |
| ORR | Objective Response Rate |
| ONC | Oncologists |
| OS | Overall Survival |
| PVP | Payer Value Proposition |
| PS | Performance status |
| PK | PhamacoKinetic |
| Portable Document File | |
| P&R | Price & Reimbursement |
| P&MA | Pricing & Market Access |
| PCP | Primary Care Provider |
| PE | Primary Endpoint |
| PI | Principal Education |
| PFS | Progression Free Survival |
| Q&A | Question and Answers |
| RET | Rearranged during transfection (proto oncogene) |
| R&D | Research & Development |
| RoW | Rest of the World |
| ROI | Return on Investment |
| SoC | Standard of Care |
| T/C | Teleconference |
| TL | Thought Leader |
| TBC | To Be Confirmed |
| TBD | To Be Determined |
| Tx | Treatment |
| Rx | Prescription Treatment |
| TRAE | Treatment Related Adverse Events |
| TKI | Tyrosine Kinase Inhibitor |
| USA | United States of America |
| UC | Urothelial Cancer |
| VEGF(R) | Vascular Endothelial Growth Factor (Receptor) |
| WG | Working group |
| WCGI | World Congress on GI Cancer |
| WKCD | World Kidney Cancer Day |